Parnell acquires Noble Pharma

Parnell has acquired Noble Pharma LLC, a pharmaceutical manufacturer based in Menomonie, Wisconsin. This acquisition adds an FDA- and DEA-accredited manufacturing facility to Parnell's operations, strengthening its capabilities in the U.S. market. The transaction, formalized under a Securities Purchase Agreement on November 26, 2025, aims to bolster Parnell's supply chain and enable the company to better meet its growing demand.

The acquisition is pivotal for Parnell, an Australian veterinary pharmaceutical company known for its animal health solutions. By integrating Noble Pharma's operational strengths and established U.S. manufacturing footprint, Parnell aims to enhance its production capabilities. The move is expected to support the company's strategic goal of providing consistent supply and superior quality products to its customers and distribution partners. Brad McCarthy, Parnell's CEO, emphasized that Noble Pharma's assets will facilitate improved supply continuity and the company's expansion strategy in the U.S.

This acquisition aligns with Parnell's growth trajectory in the American market, where it looks to scale production and accelerate product innovation to enhance customer service. Noble Pharma’s facility, which manufactures a diverse range of pharmaceutical forms including tablets, liquids, and creams, will contribute to diversifying Parnell's manufacturing capabilities. This diversity is crucial for expanding its portfolio of companion and production animal products, catering to a larger client base across the globe.

The deal occurs at a time when the pharmaceutical manufacturing sector is under pressure to ensure robust supply chains and meet rising demand in animal health products. By acquiring a U.S. production facility, Parnell positions itself to better manage logistical challenges and compete effectively in the North American market. This strategic acquisition could influence similar moves by competitors seeking to enhance manufacturing resilience and market presence.

The details of the acquisition, such as financial terms, remain undisclosed. As Parnell integrates Noble Pharma into its operations, industry observers will be watching for any strategic adjustments and further expansion moves that may follow. The acquisition does not appear to be subject to regulatory approval hurdles, suggesting a relatively straightforward path to integration in the near term.